Chinese Biotech Qinghui Lianuo Raises Nearly RMB 200 Million in Series A to Advance CAR-γδ T Cell Therapies

6Month9On [date], Qinghui Liannuo announced the completion of nearly2100 million yuanAEquity Financing Round. Investors in this round include Longpan Investment, Zhongguancun Capital, Beijing Medical and Health Industry Investment Fund, Feitu Hongyuan, and SCGC. The funds raised will be primarily used for clinical studies of core products, proof-of-concept for early-stage innovative pipelines, and the company’s independent intellectual property rights.γδ TContinuous Iterative Upgrading of the Cell Technology Platform.

Based on the team's over twenty years of experience inγδ T/BTNLeveraging its accumulated research expertise in the field of immune mechanisms, Qinghui Liannuo has independently constructed a comprehensive coverage ofγδ TA proprietary technology platform for the entire cell development value chain, with precise regulationBTNProtein Family——This controlTCell activation“Molecular Switch”——Focusing on Differentiated Innovation in Immunotherapy.

Over the past year and more, Qinghui Liannuo has seen continuous good news in its pipeline R&D:

2025Year3Month, the company announced its first independently developed targetedB7H3Allogeneic Off-the-ShelfCAR-γδ TCell TherapyQH104AOfficially Obtained in the United StatesFDAOrphan Drug Designation (ODD), for the treatment of malignant glioma.

QH104Ais a targetedB7H3Universal allogeneicCAR-γδ TCell therapy, which achieves precise tumor killing through a dual mechanism: on one hand, based on"γδ TCR-BTN-Phosphorus Antigen"Signaling pathways identify abnormal tumor metabolites; on the other hand, through chimeric antigen receptors (CAR) Specific recognition of tumor-overexpressed antigensB7H3, thereby achieving a dual-targeting effect that significantly enhances anti-tumor efficacy and safety.

2025Year5Month,QH104AOfficially Approved by the U.S.FDAClinical Trials of New Drugs (IND) approval for the treatment of recurrent or progressive high-grade glioma. It is claimed that,QH104is the world's first to obtainFDA INDApprovedCAR-γδ TCell-based candidate drugs.

2025Year9Month,QH104AOfficially approved by the Center for Drug Evaluation of the National Medical Products Administration of China (CDE) of implied clinical trial approval, intended for the treatment of recurrent or progressive malignant central nervous system tumors.

2025Year12Month,QH104ASuccessfully completed the administration of treatment to the first patient with recurrent or progressive malignant central nervous system tumors.

BesidesQH104A, the company also has several other pipeline products under development, includingCD19TargetedCAR-γδ TCell Therapy、CD19/BCMADual-targetingCAR-γδ TCell therapy, etc.

Leveraging the unique immune recognition mechanism of γδ TCR/BTN, the company’s existing CAR-T(including autologous or allogeneic CAR, in vivo CAR)In multiple hematologic and solid tumor indications with suboptimal performance or technical challenges, innovative products with novel mechanisms of action have been deployed.